Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatini...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2020-05, Vol.13 (2), p.534-537
Main Authors: Sobash, Philip T., Guddati, Achuta K., Kota, Vamsi
Format: Article
Language:English
Subjects:
Biopsy
Blood
Bone marrow
Case Report
Case reports
chronic myelogenous leukemia
complete molecular remission
Drug dosages
Hematology
Inhibitor drugs
Kinases
Leukemia
Literature reviews
major molecular response
Mutation
Patients
refractory
Remission (Medicine)
Targeted cancer therapy
tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.
ISSN:1662-6575
1662-6575
DOI:10.1159/000506895